MedPage Today, LLC

Website Links

Description

Benefit of New Taxane Affirmed in Prostate CA 9/30/2010 The recently approved chemotherapy agent cabazitaxel (Jevtana) improves overall survival in metastatic, hormone-refractory prostate cancer resistant to docetaxel (Taxotere), researchers affirmed. AACR: Protein Array Accurate for Prostate CA 9/30/2010 DENVER -- A panel of prostate cancer-derived autoantibodies distinguished cancer from benign prostatic hyperplasia and healthy tissue with greater than 90% accuracy, according to a preliminary study reported here. No Prostate Cancer Indication for Sunitinib 9/28/2010 A phase IIIa trial of the tyrosine kinase inhibitor sunitinib (Sutent) in patients with advanced castration-resistant prostate cancer has been halted for lack of efficacy, the drug's manufacturer announced. Risks Top Benefits of Screening in Men With Low PSA 9/13/2010 Men with low prostate-specific antigen (PSA) values may face more risks than benefits from aggressive approaches to prostate cancer screening and evaluation -- along with potential overtreatment -- data from a large cohort study suggest. Cost of Prostate Cancer Therapy Varies Widely 8/23/2010 The five-year cost of treating localized prostate cancer varied by as much as 200%, depending on the choice of initial therapy, analysis of an NIH database showed. Tests, Not Genes, May Fuel Diagnosis of Prostate CA 8/20/2010 Brothers of prostate cancer patients have higher rates of the disease and higher rates of clinically insignificant cancer because they have more diagnostic tests, data from a large cohort study indicated. FDA Dings Prostate CA Drugmaker on Marketing 8/13/2010 The maker of the prostate cancer immunotherapy sipuleucel-T (Provenge) has exaggerated the therapy's efficacy and played down its risks in some marketing materials, the FDA charged.

Products & services

Similar companies nearby